StudyID,Drug_Name,Prot_No,NCT_No,EUCT_No,Other_No,Inv_Prod,Study_Phase,Start_Date,Termin_Date,Complet_Date,Data_Cutoff_Date,Name_PI,Sponsor,GCP_Compliance,Study_First_Posted_Date,Route_Admin,Treat_Duration,Add_On_Treat,Arm_Description,Adherence_Treat,MRCT,No_Center,No_Center_NA,No_Center_AP,No_Center_WEU,No_Center_EEU,No_Center_AF,Enroll_Duration_Plan,FU_Duration_Plan,Central_Lab,Run_in,DMC
NCT02039674,Pembrolizumab; Paclitaxel; Carboplatin; Bevacizumab; Pemetrexed; Ipilimumab; Erlotinib; Gefitinib,3475-021,NCT02039674,,MK-3475-021; KEYNOTE-021,Pembrolizumab; Paclitaxel; Carboplatin; Bevacizumab; Pemetrexed; Ipilimumab; Erlotinib; Gefitinib,Phase 1/Phase 2,"February 21, 2014",,"October 18, 2021",,,Merck Sharp & Dohme LLC,,"January 17, 2014",,,,Part 1 Cohort A2 (Pembro2mg/kg+Paclitaxel [Pa]+Carboplatin [C]): Cohort A participants receive pembrolizumab (2 mg/kg) via intravenous (IV) infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (Aare Under the Curve [AUC] 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.; Part 1 Cohort B2 (Pembro 2mg/kg+Pa+C+Bevacizumab [B]): Cohort B2 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS bevacizumab (15 mg/kg) via IV infusion on Day 1 of each 3-week cycle.; Part 1 Cohort C2 (Pembro 2mg/kg+Pemetrexed [Pe]+C): Cohort C2 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.; Part 1 Cohort D1 (Pembro 10mg/kg+Ipilimumab [I]): Cohort D1 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle.; Part 1 Cohort E (Pembro 2mg/kg+Erlotinib): Cohort E participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS erlotinib (150 mg) via oral tablet once a day on every day of each 3-week cycle.; Part 1 Cohort F (Pembro 2mg/kg+Gefitinib): Cohort F participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS gefitinib (250 mg) via oral tablet once a day on every day of each 3-week cycle.; Part 2 Cohort G+ (Pembro 200mg+C+Pe): Cohort G+ participants receive pembrolizumab (200 mg) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle.; Part 2 Cohort H (Pembro+I): Cohort H participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle (at the recommended Phase II dose determined in Cohort D).; Part 1 Cohort A10 (Pembro+Paclitaxel [Pa]+Carboplatin [C]): Cohort A10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.; Part 1 Cohort B10 (Pembro+Pa+C+Bevacizumab [B]): Cohort B10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS bevacizumab (15 mg/kg) via IV infusion on Day 1 of each 3-week cycle.; Part 1 Cohort C10 (Pembro 10mg/kg+Pemetrexed [Pe]+C): Cohort C10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.; Part 2 Cohort G- (Placebo+C+Pe): Cohort G- participants receive placebo (normal saline solution) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS.; Part 1 Cohort D2 (Pembro 10mg/kg+Ipilimumab [I]): Cohort D2 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (3 mg/kg) via IV infusion on Day 1 of each 3-week cycle.; Part 1 Cohort D4 (Pembro 2mg/kg+Ipilimumab [I]): Cohort D1 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle.,,,,,,,,,,,,,No
